Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

被引：236
作者：
Holst, JJ [1 ]
Deacon, CF [1 ]
机构：
[1] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark
来源：
DIABETOLOGIA | 2005年 / 48卷 / 04期
关键词：
dipeptidyl peptidase-IV; gastric inhibitory polypeptide; gastroenteropancreatic peptide hormones; glucagon-like peptide-1; incretin; incretin effect; oral hypoglycaemic agents; pharmacokinetics; proteolytic processing;
D O I：
10.1007/s00125-005-1705-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：612 / 615
页数：4
相关论文
共 34 条
[1]   Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].
Ahrén, B ;
Landin-Olsson, M ;
Jansson, PA ;
Svensson, M ;
Holmes, D ;
Schweizer, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084
[2]   Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].
Ahrén, B ;
Simonsson, E ;
Larsson, H ;
Landin-Olsson, M ;
Torgeirsson, H ;
Jansson, PA ;
Sandqvist, M ;
Båvenholm, P ;
Efendic, S ;
Eriksson, JW ;
Dickinson, S ;
Holmes, D .
DIABETES CARE, 2002, 25 (05) :869-875
[3]  
AHREN B, 2004, DIABETES, V53
[4]   Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms [J].
Balkan, B ;
Li, X .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2000, 279 (04) :R1449-R1454
[5]   Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor [J].
Burcelin, R ;
Da Costa, A ;
Drucker, D ;
Thorens, B .
DIABETES, 2001, 50 (08) :1720-1728
[6]   Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients [J].
Creutzfeldt, WOC ;
Orskov, C ;
Kleine, N ;
Holst, JJ ;
Willms, B ;
Nauck, MA .
DIABETES CARE, 1996, 19 (06) :580-586
[7]   Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region [J].
Dardevet, D ;
Moore, MC ;
Neal, D ;
DiCostanzo, CA ;
Snead, W ;
Cherrington, AD .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 287 (01) :E75-E81
[8]   Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs [J].
Deacon, CF ;
Wamberg, S ;
Bie, P ;
Hughes, TE ;
Holst, JJ .
JOURNAL OF ENDOCRINOLOGY, 2002, 172 (02) :355-362
[9]   BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].
DEACON, CF ;
NAUCK, MA ;
TOFTNIELSEN, M ;
PRIDAL, L ;
WILLMS, B ;
HOLST, JJ .
DIABETES, 1995, 44 (09) :1126-1131
[10]   DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].
DEACON, CF ;
JOHNSEN, AH ;
HOLST, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957
1234